A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Public ClinicalTrials.gov record NCT07176390. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses of tulisokibart works better than a placebo to lessen RA symptoms. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of the study medicine.
Study identification
- NCT ID
- NCT07176390
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 182 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 7, 2025
- Primary completion
- Sep 4, 2026
- Completion
- Mar 2, 2029
- Last update posted
- Jun 11, 2026
2025 – 2029
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Arthritis & Rheumatology Associates, P.C. ( Site 1018) | Glendale | Arizona | 85306-9802 | — |
| AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa ( Site 1033) | Mesa | Arizona | 85210 | — |
| Arthritis & Osteoporosis Medical Center - La Palma ( Site 1024) | La Palma | California | 90623 | — |
| Tekton Research, LLC. ( Site 1008) | Fort Collins | Colorado | 80528 | — |
| Sweet Hope Research Specialty, Inc ( Site 1015) | Hialeah | Florida | 33016 | — |
| HMD Research LLC ( Site 1016) | Orlando | Florida | 32819 | — |
| Greater Chicago Specialty Physicians - Orland Park ( Site 1043) | Orland Park | Illinois | 60467 | — |
| AA Medical Research Center ( Site 1027) | Grand Blanc | Michigan | 48439 | — |
| Kansas City Physician Partners ( Site 1032) | Kansas City | Missouri | 64111 | — |
| Physician Research Collaboration, LLC ( Site 1002) | Lincoln | Nebraska | 68516 | — |
| altoona center for clinical research ( Site 1005) | Duncansville | Pennsylvania | 16635 | — |
| Rheumatology Specialty Center ( Site 1030) | Willow Grove | Pennsylvania | 19090 | — |
| AARA Clinical Research - Murfreesboro Medical Clinic ( Site 1034) | Murfreesboro | Tennessee | 37128 | — |
| Rheumatology Associates ( Site 1026) | Arlington | Texas | 76012 | — |
| Epic Medical Research ( Site 1004) | Red Oak | Texas | 75154 | — |
| Advanced Rheumatology of Houston - Woodlands ( Site 1000) | The Woodlands | Texas | 77382 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07176390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07176390 live on ClinicalTrials.gov.